{"id":2616,"date":"2016-08-05T18:17:00","date_gmt":"2016-08-05T18:17:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2616"},"modified":"2025-01-15T20:25:51","modified_gmt":"2025-01-15T20:25:51","slug":"chronic-hepatitis-c-virus-hcv-burden-in-rhode-island-modelling-treatment-scale-up-and-elimination","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/chronic-hepatitis-c-virus-hcv-burden-in-rhode-island-modelling-treatment-scale-up-and-elimination\/","title":{"rendered":"Fardeau du virus de l&#039;h\u00e9patite C chronique (VHC) au Rhode Island: mod\u00e9lisation de l&#039;extension et de l&#039;\u00e9limination du traitement"},"content":{"rendered":"<h2 class=\"wp-block-heading\">R\u00e9sum\u00e9<\/h2>\n\n\n\n<p>Nous avons utilis\u00e9 un mod\u00e8le de progression de la maladie pour pr\u00e9dire le nombre d&#039;infections vir\u00e9miques, de cas cirrhotiques et de d\u00e9c\u00e8s li\u00e9s au foie dans l&#039;\u00c9tat de Rhode Island (RI) selon quatre sc\u00e9narios de traitement : (1) paradigme actuel de traitement du VHC (environ 215 patients trait\u00e9s chaque ann\u00e9e, crit\u00e8res de remboursement Medicaid stade de fibrose \u2a7eF3) ; (2) intensification imm\u00e9diate du traitement (\u00e0 430 par an) et crit\u00e8res de remboursement Medicaid moins restrictifs (stade de fibrose \u2a7eF2) ; (3) intensification imm\u00e9diate du traitement et aucun crit\u00e8re de remboursement Medicaid sp\u00e9cifique au stade de fibrose (\u2a7eF0) ; (4) un sc\u00e9nario \u00ab d&#039;\u00e9limination \u00bb (c&#039;est-\u00e0-dire une intensification continue du traitement n\u00e9cessaire pour atteindre une r\u00e9duction &gt;90% des cas vir\u00e9miques d&#039;ici 2030). Selon les mod\u00e8les de traitement actuels, le nombre de cas cirrhotiques et de d\u00e9c\u00e8s li\u00e9s au foie atteindra un plateau et un pic d&#039;ici 2030, respectivement. Fran\u00e7ais L&#039;intensification du traitement avec des crit\u00e8res de traitement de stade de fibrose \u2a7eF2 et \u2a7eF0 pourrait r\u00e9duire le nombre de cas cirrhotiques de 21,7% et 10,0%, et le nombre de d\u00e9c\u00e8s li\u00e9s au foie de 19,3% et 7,4%, respectivement d&#039;ici 2030. Pour atteindre une r\u00e9duction &gt;90% des cas vir\u00e9miques d&#039;ici 2030, plus de 2000 personnes devront \u00eatre trait\u00e9es chaque ann\u00e9e d&#039;ici 2020. Cette strat\u00e9gie pourrait r\u00e9duire les cas de cirrhose et les d\u00e9c\u00e8s li\u00e9s au foie de 78,9% et 72,4%, respectivement d&#039;ici 2030. Une augmentation du recours au traitement du VHC est n\u00e9cessaire pour r\u00e9duire consid\u00e9rablement la charge du VHC d&#039;ici 2030 dans le Rhode Island.<\/p>\n\n\n\n<p><strong>Des pays:<\/strong> \u00c9tats-Unis - Rhode Island<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27492142\" target=\"_blank\" rel=\"noreferrer noopener\">Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary We utilized a disease progression model to predict the number of viraemic infections, cirrhotic cases, and liver-related deaths in the state of Rhode Island (RI) under four treatment scenarios: (1) current HCV treatment paradigm (about 215 patients treated annually, Medicaid reimbursement criteria fibrosis stage \u2a7eF3); (2) immediate scale-up of treatment (to 430 annually) and [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3303,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[31,10,12],"publication-author":[1103,1106,494,497,1104,1105],"class_list":["post-2616","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-elimination","tag-hcv","tag-modelling","publication-author-galarraga-o","publication-author-marshall-bdl","publication-author-razavi-h","publication-author-razavi-shearer-d","publication-author-soipe-ai","publication-author-taylor-le"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=2616"}],"version-history":[{"count":6,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2616\/revisions"}],"predecessor-version":[{"id":7574,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2616\/revisions\/7574"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3303"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=2616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=2616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=2616"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=2616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}